Biotech & Pharma

Opinion: I was a Moderna exec when the Covid vaccine rolled out. That spirit of possibility is no more

24 sec read9 views0 listens

A former Moderna executive reflects on the decline of innovation spirit at the company post-Covid vaccine rollout, highlighting regulatory uncertainty and trust issues; the FDA's reversal in reviewing ModernaG??s flu vaccine application underscores ongoing challenges for pharmaceutical innovators. Content creators should emphasize transparency and maintain public trust when reporting on medical advancements and regulatory decisions.

Read the full article at STAT Pharma

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Legal & Policy16 hours ago26 sec read

What the public thinks of the Supreme Court

The Marquette Law School Poll reveals a 47% approval rating for the Supreme Court, with significant partisan divides: 74% of Republicans approve compared to only 22% of Democrats. Public perception of the court's alignment with President Trump also v...

Ali Nemati

Legal & Policy2 days ago21 sec read

Today At ILTACON: ILTA Swag, Lessons In Leadership, Game Night

The 46th annual ILTACON conference is underway with over 5,300 attendees and a packed schedule of panels, educational sessions, and networking events. Key highlights include swag giveaways, leadership book launches, wellness stations, and AI-focused ...

Ali Nemati

Finance & Crypto2 days ago25 sec read

Leadership Succession Planning: Protect Your CEO Legacy

Leadership succession planning is critically under-resourced, with only 21% of HR leaders reporting formal plans in place, leading to significant risks for market value and strategic continuity. This gap highlights the need for CEOs to treat successi...

Ali Nemati